Syntis Bio, Inc.
PrivateLast Round
Series A
Jul 1, 2025
Est. Valuation
$67M
Total Funding Raised
$53.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Syntis Bio, Inc. is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine's biology for conditions like obesity, diabetes, and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Syntis Bio, Inc. Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Syntis Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 1, 2025 | ||||
| Grant | Jul 1, 2025 |
Syntis Bio, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| Cerity Partners Ventures | Series A, Seed |
| Cerberus Ventures | Series A |
| Mansueto Office | Series A |
| Woori Venture Partners Co., Ltd. | Series A |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| Colorcon Ventures | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 11, 2026
David Rosenbaum appointed as Chief Development Officer.
- Mar 3, 2026
Christo Shalish appointed as the new Chief Business Officer.
Syntis Bio, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Syntis Bio, Inc.'s valuation, stock price, and market status.